Sitemap

Posts by category

• Category: News
  • Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025 
  • Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant 
  • Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease 
  • Malewana et al. (2025) “Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates” Science Translational Medicine.
  • Aunins et al. (2025) “An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses” Science Immunology.
  • Rothgangl et al. (2025) “Treatment of a metabolic liver disease in mice with a transient prime editing approach” Nature Biomedical Engineering.
  • Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025 
  • Musunuru et. al (2025) “Patient-specific in vivo gene editing to treat a rare genetic disease” The New England Journal of Medicine.
  • Kissling et al. (2025) “Predicting adenine base editing efficiencies in different cellular contexts by deep learning” Genome Biology.
  • Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
  • Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025
  • Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024
  • PUBLICATION ALERT: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery
  • Papp et al. (2025) “CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery” Molecular Therapy.
  • PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
  • Broomfield et al. (2025) “Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection” Journal of Experimental Medicine.
  • PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT
  • Blizard et al. (2025) “Monitoring mRNA vaccine antigen expression in vivo using PET/CT” Nature Communications.
  • PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA
  • Yanik et al. (2025) “iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA” NPJ Vaccines.
  • Acuitas Therapeutics’ Chief Legal Officer Miranda Lam Appointed as King’s Counsel
  • Dr. Ghania Chikh Named Senior Director, Vaccine Development at Acuitas Therapeutics
  • Acuitas Therapeutics’ President & CEO Named a National Winner in the EY Canadian Entrepreneur of the Year Program
• Category: Presentations
  • An Alternative Method to RNA Lipid Nanoparticle Production
  • Evolving Lipid Nanoparticles to Optimize Clinical Application of messenger RNA Therapeutics
  • Pharmacodynamic Activity, Pharmacokinetics and Tolerability of Lipid Nanoparticle Formulations of mRNA Following Repeated Intravenous Dosing in Monkeys 
  • Delivery, Potency, and Tolerability of Lipid Nanoparticle Formulations of mRNA in PXB-mice
  • Improved T Cell Delivery and Expression of mRNA Using CD8-Targeted Lipid Nanoparticles with Athebody® Designed Ankyrin Repeat Proteins (DARPins)
  • Development of LNP for mRNA Cancer Immunotherapy (Presentation)
  • Development of LNP for mRNA Cancer Immunotherapy (Poster)
  • Identification of Novel Lipids with Improved Activity for Prophylactic Vaccine Development
  • Optimizing Ionizable Lipid & LNP Properties to Improve Safety
  • mRNA Therapeutics Delivery with Next Generation Ionizable Lipids
  • Identification of Novel Lipids With Improved Activity for Prophylactic Vaccine Development
• Category: Publications
  • Shuvaev et al. (2025) “Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo” PNAS.
  • Surisaeng et al. (2025) “BMP-2 mRNA-transfected BMSCs promote superior calvarial bone regeneration” Scientific Reports.
  • Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025
  • Acuitas Therapeutics named one of BC’s Top Employers of 2025
  • Tremblay et al. (2025) “A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels” Nature Medicine.
  • PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays
  • Imiolek et al. (2025) “High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays” Analytical Chemistry.
  • PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by  in situ delivery of RNA lipid nanoparticles
  • Banda et al. (2025) “Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles” Molecular Therapy.
  • Smith et al. (2024) “Impact of metabolic states on SARS-CoV-2 vaccine responses in mouse models of obesity and diabetes” MDPI.
  • Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit
  • Abt et al. (2024) “Staggered immunization with mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire” PNAS.
  • Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
  • Acuitas Therapeutics Honoured With Philanthropic Award
  • Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
  • Castruccio Castracani et al. (2024) “An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA” Blood.
  • Chappell et al. (2024) “Use of HSC targeted LNP to generate a mouse model of lethal α-Thalassemia and treatment via lentiviral gene therapy” Blood.
  • Leonard et al. (2024) “Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA” Nature Communications.
  • PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
  • Cohen et al. (2024) “Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals” Cell.
  • Alameh et al. (2024) “A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection” Science.
  • Atochina-Vasserman et al. (2024) “Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection” NPJ Vaccines.
  • Kafle et al. (2024) “The roles of CD4+ T cell help, sex, and dose in the induction of protective CD8+ T cells against a lethal poxvirus by mRNA-LNP vaccines” Molecular Therapy Nucleic Acids.
  • Kuzmin et al. (2024) “Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine” Nature Communications.
  • Guenaga et al. (2024) “mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies” Frontiers in Immunology.
  • Christopher Sweeney Named Executive Director, Intellectual Property
  • England et al. (2024) “Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model” NPJ Vaccines.
  • Smith et al. (2024) “Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice” Nature Communications.
  • Parhiz et al. (2024) “Physiologically-based modeling of LNP-mediated delivery of mRNA in the vascular system” Molecular Therapy Nucleic Acids.
  • Montoya et al. (2024) “mRNA-LNP vaccine-induced CD8+ T-cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies” Molecular Therapy.
  • Furey et al. (2024) “Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus” Nature Communications.
  • Wiehe et al. (2024) “Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction” Cell Host & Microbe.
  • Acuitas Poster Presentations at ASGCT Annual Meeting
  • Nong et al. (2024) “Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke” Molecular Therapy.
  • Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024
  • Tafech et al. (2024) “Exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions” Advanced Healthcare Materials.
  • Tilsed et al. (2024) “IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation” PNAS.
  • Birdsall et al. (2024) “Monitoring stability indicating impurities and aldehyde content in lipid nanoparticle raw material and formulated drugs” Journal of ChromatographyB.
  • Acuitas Therapeutics Named One of BC’s Top Employers of 2024
  • Matias et al. (2024) “mRNA vaccination of rabbits alters the fecundity, but not the attachment, of adult Ixodes scapularis” Scientific Reports.
  • Kunkeaw et al. (2023) “A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax” NPJ Vaccines.
  • Breda et al. (2023) “In vivo hematopoietic stem cell modification by mRNA delivery” Science.
  • Hoffmann et al. (2023) “ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines” Cell.
  • Gál et al. (2023) “Restoration of motor function through delayed intraspinal delivery of human IL-10-encoding nucleoside-modified mRNA after spinal cord injury” Research.
  • Connors et al. (2023) “Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals” Communications Biology.
  • Schiepers et al. (2023) “Molecular fate-mapping of serum antibody responses to repeat immunization” Nature.
  • Arevalo et al. (2022) “A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes” Science.
  • Gorsuch et al. (2022) “Targeting the Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo” Molecular Therapy.
  • Pardi et al. (2022) “Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses” Nature Communications.
  • Mu et al. (2022) “mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice” Cell Reports.
  • Rurik et al. (2022) “CAR T cells produced in vivo to treat cardiac injury” Science.
  • Mallory et al. (2021) “Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice” NPJ Vaccines.
  • Musunuru et al. (2021) “In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates” Nature.
  • Rothgangl et al. (2021) “In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels” Nature Biotechnology.
  • Rizvi et al. (2021) “Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA” Nature Communications.
  • Villiger et al. (2021) “In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA” Nature Biomedical Engineering.
  • Weissman et al. (2021) “D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization” Cell Host & Microbe.
  • Lederer et al. (2020) “SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation” Immunity.
  • Laczkó et al. (2020) “A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice” Immunity.
  • McKay et al. (2020) “Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice” Nature Communications.
  • Freyn et al. (2020) “A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice” Molecular Therapy.
  • Raj et al. (2020) “Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria” Nature.
  • Marcos-Contreras (2020) “Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier” PNAS.
  • Willis et al. (2020) “Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice” Science Translational Medicine.
  • Huysmans et al. (2019) “Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin” Molecular Therapy Nucleic Acids.
  • Pardi et al. (2019) “Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques” Molecular Therapy Nucleic Acids.
  • Conway et al. (2019) “Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets” Molecular Therapy.
  • Parhiz et al (2018) “PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake” Journal of Controlled Release.
  • Pardi et al. (2018) “Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies” Nature Communications.
  • Pardi et al. (2018) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine.
  • Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines.
  • Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine.
  • Pardi et al. (2017) “Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge” Nature Communications.
  • Pardi et al. (2017) “Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature.
  • Pardi et al. (2015) “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes” Journal of Controlled Release.
  • Thess et al. (2015) “Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals” Molecular Therapy.
  • Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Molecular Therapy.
  • Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Molecular Therapy Nucleic Acids.
  • Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angewandte Chemie.
  • Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Molecular Therapy.
  • Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nature Biotechnology.